Lymphomatoid granulomatosis
| Lymphomatoid granulomatosis | |
|---|---|
| Classification and external resources | |
| ICD-O: | 9766/1 |
| DiseasesDB | 33208 |
| eMedicine | med/1369 |
| MeSH | D008230 |
Lymphomatoid granulomatosis is a neoplastic disease.
It is a lymphoproliferative disorder (lymphomatoid means lymphoma-like). The word granulomatosis denotes one of its microscopic character, polymorphic lymphoid infiltrates and focal necrosis within it.
While most commonly found in older patients, in 2008 the youngest patient ever (13) was diagnosed with this cancer.[citation needed]
It usually involves lung, skin, and central nervous system.
It was first characterized in 1972.[1]
Contents |
[edit] Causes
It is induced by Epstein Barr virus.[2]
[edit] Prognosis
There is no known cure. It is resistant to ordinary chemotherapy.[3]
There currently is a protocol being run by Dr. Wyndham H. Wilson at the NIH. The experimental treatment involves the use of interferons.[4]
[edit] See also
[edit] References
- ^ Liebow AA, Carrington CR, Friedman PJ (1972). "Lymphomatoid granulomatosis". Hum. Pathol. 3 (4): 457–558. doi:10.1016/S0046-8177(72)80005-4. PMID 4638966.
- ^ Agarwal V, Agarwal A, Pal L, Misra R (February 2004). "Arthritis in lymphomatoid granulomatosis: report of a case and review of literature". Indian J Med Sci 58 (2): 67–71. PMID 14993719. http://www.indianjmedsci.org/article.asp?issn=0019-5359;year=2004;volume=58;issue=2;spage=67;epage=71;aulast=Agarwal.
- ^ Oosting-Lenstra SF, van Marwijk Kooy M (2007). "Failure of CHOP with rituximab for lymphomatoid granulomatosis". Neth J Med 65 (11): 442–7. PMID 18079567. http://www.zuidencomm.nl/njm/getarticle.php?v=65&i=11&p=442.
- ^ "National Cancer Institute: Clinical Trials at NIH: Clinical Research: Clinical Trial Spotlight: Lymphomatoid Granulomatosis NCI-94-C-0074". http://bethesdatrials.cancer.gov/Wilson/94c0074/default.asp. Retrieved 2007-09-04.
 |
This disease article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
